Article
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Drug metabolism and pharmacokinetics - 1 Apr 2022
Maekawa Keiko, Yamamura Masahiro, Matsuki Atsushi, Ishikawa Takashi, Hirai Toshihiro, Yamaguchi Yoshiyuki, Saito Yoshiro, Kanda Tatsuo
Abstract excerpt
Although imatinib has dramatically improved the outcomes of patients with gastrointestinal stromal tumor (GIST), marked inter-individual differences in its efficacy and toxicity have been observed. Extensive pharmacogenetic studies in Caucasian and Asian populations have demonstrated that several genetic polymorphisms are involved in these differences; however, no studies have focused on Japanese patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.